Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study

BACKGROUND: PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. Whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zheng, Ma, Jialin, Yao, Shuna, Yao, Zhihua, Wang, Haiying, Chu, Junfeng, Zhao, Shuang, Liu, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664390/
https://www.ncbi.nlm.nih.gov/pubmed/34899689
http://dx.doi.org/10.3389/fimmu.2021.727464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664390/
https://www.ncbi.nlm.nih.gov/pubmed/34899689
http://dx.doi.org/10.3389/fimmu.2021.727464

Ejemplares similares